Deleobuvir (formerly BI 207127) was an experimental drug for the treatment of

hepatitis C Hepatitis C is an infectious disease caused by the hepatitis C virus (HCV) that primarily affects the liver; it is a type of viral hepatitis. During the initial infection people often have mild or no symptoms. Occasionally a fever, dark urine, a ...

. It was being developed by Boehringer Ingelheim. It is a non-nucleoside

hepatitis C virus The hepatitis C virus (HCV) is a small (55–65 nm in size), enveloped, positive-sense single-stranded RNA virus of the family ''Flaviviridae''. The hepatitis C virus is the cause of hepatitis C and some cancers such as liver cancer ( hepato ...

NS5B polymerase inhibitor. Deleobuvir was tested in combination regimens with

pegylated interferon Pegylated interferon (PEG-IFN) is a class of medication that includes three different drugs as of 2012: * Pegylated interferon-alpha-2a * Pegylated interferon-alpha-2b * Pegylated interferon-beta-1a In these formulations, Polyethylene glycol (PEG ...

and

ribavirin Ribavirin, also known as tribavirin, is an antiviral medication used to treat RSV infection, hepatitis C and some viral hemorrhagic fevers. For hepatitis C, it is used in combination with other medications such as simeprevir, sofosbuvir, pe ...

, and in interferon-free regimens with other direct-acting antiviral agents including

faldaprevir Faldaprevir was an experimental drug for the treatment of hepatitis C (HCV). It was being developed by Boehringer-Ingelheim and reached Phase III clinical trials in 2011. Boehringer announced in 2014 that it would not pursue approval of the dru ...

. Data from the SOUND-C2 study, presented at the 2012 AASLD Liver Meeting, showed that a triple combination of deleobuvir,

, and

performed well in HCV genotype 1b patients. Efficacy fell below 50%, however, for dual regimens without ribavirin and for genotype 1a patients. These results were confirmed in the SOUND-C3 study, presented at the 2013 APASL Liver Conference, which found that 16-week triple therapy with deleobuvir +

gave 95% SVR12 in HCV genotype 1b patients but poor virological response in genotype 1a. In December 2013, Boehringer Ingelheim announced that the development of deleobuvir would not be continued since recent findings from phase III trials did not suggest sufficient efficacy.

References

Abandoned drugs NS5A inhibitors Pyrimidines Bromoarenes Benzimidazoles Cyclobutanes Cyclopentanes {{Antiinfective-drug-stub